{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:34:49Z","timestamp":1745469289800,"version":"3.40.4"},"reference-count":20,"publisher":"S. Karger AG","issue":"7-8","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Res Treat"],"published-print":{"date-parts":[[2013]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background: &lt;\/i&gt;&lt;\/b&gt;Prognosis and survival for patients with metastatic soft tissue sarcoma (STS) are dismal. Standard first-line systemic chemotherapy is anthracycline-based. Gemcitabine\/docetaxel (GD) is a therapeutic option in the second-line setting. Here we present the data of our single center retrospective analysis, using GD in locally advanced or metastatic disease. &lt;b&gt;&lt;i&gt;Patients and Methods: &lt;\/i&gt;&lt;\/b&gt;Between 2005 and 2012, a total of 34 patients were identified. The majority of tumors were located in the extremities (19\/34, 56%) and abdomen\/retroperitoneum (10\/34, 29%). Most frequent histologies included leiomyosarcoma (13\/34, 38%), liposarcoma (7\/34, 21%), and pleomorphic sarcoma (6\/34, 18%). &lt;b&gt;&lt;i&gt;Results: &lt;\/i&gt;&lt;\/b&gt;Objective response to treatment by RECIST criteria after 3 cycles was low with 6% partial responses (PR, 2\/34), 65% stable disease (SD, 22\/34), and 29% progressive disease (PD, 10\/34). Progression-free survival at 3 and 6 months was 77 and 62%, respectively. Patients with a clinical benefit (defined as PR or SD after the 3rd treatment cycle) had a significantly prolonged median progression-free and overall survival with 8.6 months (p &lt; 0.0001; hazard ratio (HR) 33.1) and 22.4 months (p &lt; 0.0001; HR 12.9), respectively. Most common toxicities included hand-foot syndrome, edema, pancytopenia, febrile neutropenia, and mucositis. &lt;b&gt;&lt;i&gt;Conclusion: &lt;\/i&gt;&lt;\/b&gt;Overall, we conclude that GD is an active second-line regimen in metastatic STS, with manageable side effects.<\/jats:p>","DOI":"10.1159\/000353564","type":"journal-article","created":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T08:21:37Z","timestamp":1374135697000},"page":"415-420","source":"Crossref","is-referenced-by-count":6,"title":["Gemcitabine and Docetaxel for Metastatic Soft Tissue Sarcoma - a Single Center Experience"],"prefix":"10.1159","volume":"36","author":[{"given":"Thomas","family":"Schmitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florentina","family":"Kosely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Wuchter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann-Wilhelm","family":"Schmier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony D.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerlinde","family":"Egerer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2013,7,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20073"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)90286-0"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003293"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.7717"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.13-S2-14"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20769"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32832c95e2"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00398-7"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.028"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.180"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.210"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60651-5"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21867"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.4117"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0467"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.050"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.03.010"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.11.027"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159\/0000111756"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2012.44.1.43"}],"container-title":["Oncology Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/353564","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/353564","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:37:34Z","timestamp":1745433454000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000353564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":20,"journal-issue":{"issue":"7-8","published-online":{"date-parts":[[2013,8,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000353564","archive":["Portico"],"relation":{},"ISSN":["2296-5270","2296-5262"],"issn-type":[{"type":"print","value":"2296-5270"},{"type":"electronic","value":"2296-5262"}],"subject":[],"published":{"date-parts":[[2013]]}}}